-
Functional Areas
- Audit and Investigations
-
Capacity development and transition, strengthening systems for health
- A Strategic Approach to Capacity Development
- Capacity Development and Transition - Lessons Learned
- Capacity development and Transition Planning Process
- Capacity Development and Transition
- Capacity Development Objectives and Transition Milestones
- Capacity Development Results - Evidence From Country Experiences
- Functional Capacities
- Interim Principal Recipient of Global Fund Grants
- Legal and Policy Enabling Environment
- Overview
- Resilience and Sustainability
- Transition
-
Financial Management
- CCM Funding
- Grant Closure
- Grant Implementation
- Grant-Making and Signing
- Grant Reporting
- Import duties and VAT / sales tax
- Overview
- Sub-recipient Management
-
Grant closure
- Overview
-
Steps of Grant Closure Process
- 1. Global Fund Notification Letter 'Guidance on Grant Closure'
- 2. Preparation and Submission of Grant Close-Out Plan and Budget
- 3. Global Fund Approval of Grant Close-Out Plan
- 4. Implementation of Close-Out Plan and Completion of Final Global Fund Requirements (Grant Closure Period)
- 5. Operational Closure of Project
- 6. Financial Closure of Project
- 7. Documentation of Grant Closure with Global Fund Grant Closure Letter
- Terminology and Scenarios for Grant Closure Process
- Human resources
- Human rights, key populations and gender
-
Legal Framework
- Agreements with Sub-recipients
- Agreements with Sub-sub-recipients
- Amending Legal Agreements
- Implementation Letters and Performance Letters
- Language of the Grant Agreement and other Legal Instruments
- Legal Framework for Other UNDP Support Roles
- Other Legal and Implementation Considerations
- Overview
- Project Document
- Signing Legal Agreements and Requests for Disbursement
-
The Grant Agreement
- Grant Confirmation: Conditions Precedent (CP)
- Grant Confirmation: Conditions
- Grant Confirmation: Face Sheet
- Grant Confirmation: Schedule 1, Integrated Grant Description
- Grant Confirmation: Schedule 1, Performance Framework
- Grant Confirmation: Schedule 1, Summary Budget
- Grant Confirmation: Special Conditions (SCs)
- Grant Confirmation
- UNDP-Global Fund Grant Regulations
-
Monitoring and Evaluation
- Differentiation Approach
- Monitoring and Evaluation Components of Funding Request
- M&E Components of Grant Implementation
- Monitoring and Evaluation Components of Grant Making
- Overview
- Principal Recipient Start-Up
-
Health Product Management
- UNDP Quality Assurance Policy
- Compliance with the Global Fund requirements
- Distribution
- Inspection and Receipt
- International freight, transit requirements and use of INCOTERMS
- Inventory Management
- Overview - Health Product Management
- Pharmacovigilance
- Product Selection
- Quality monitoring of health products
- Quantification and Forecasting
- Rational use
- Risk Management for PSM of health products
-
Sourcing and regulatory aspects
- Development of List of Health Products
- Development of the Health Procurement Action Plan (HPAP)
- Global Health Procurement Center (GHPC)
- Guidance on donations of health products
- Health Procurement Architecture
- Local Procurement of health products
- Other Elements of the UNDP Procurement Architecture
- Procurement of non-pharmaceutical Health Products
- Procurement of Pharmaceutical Products
- Submission of GHPC CO Procurement Request Form
- Storage
- Supply Planning of Health Products
- UNDP Health PSM Roster
- Waste management
- Grant Reporting
-
Risk Management
- Introduction to Risk Management
- Overview
- Risk management in crisis settings
-
Risk Management in the Global Fund
- Additional Safeguard Policy
- Challenging Operating Environment (COE) Policy
- Global Fund Review of Risk Management During Grant Implementation
- Global Fund Risk Management Framework
- Global Fund Risk Management Requirements During Funding Request
- Global Fund Risk Management Requirements for PRs
- Local Fund Agent
- Risk management in UNDP
- Risk Management in UNDP-managed Global Fund projects
- UNDP Risk Management Process
- Sub-Recipient Management
Quality Monitoring at different stages
Pre-shipment inspection, sampling and testing
For most categories of products, pre-shipment inspection and testing is not recommended. For certain categories of products, the implementation of pre-shipment inspection, sampling and testing activities may be required, as a risk mitigation measure rather than as a quality assurance mechanism.
Pre-shipment with randomized sampling and testing is required for the following product categories: Finished Pharmaceuticals Products (FPPs) recommended for procurement by the WHO Expert Review Panel (ERP); In-vitro Diagnostic Products recommended for procurement by the WHO ERP for Diagnostics (ERPD); Condoms (male and female) that are not listed in the UNFPA list; and all Vector Control products.
Post-shipment inspection, sampling and testing
UNDP COs must perform post-shipment inspection at the time of the reception of the goods by visual inspection and review of import documentation that the products received are in line with the purchase order and the specifications. UNDP GFPHST does not advise conducting routine post-shipment quality control testing, except if the information collected on transit and logistic conditions during the post-shipment inspection indicates the likelihood of a risk on the quality or the performance of the products procured.
In-country inspection, sampling and testing
In-country quality monitoring activities should consider a range of activities which are complementary to each other rather than relying on only one specific activity such as quality control testing. Activities include visual inspection of the packaging of the products focussing on reviewing the content of packaging and labelling such as spelling errors, inadequate reference to standards, expiry date.
Full quality control testing of the products is a time consuming, costly and lengthy procedure used to confirm the compliance of a product. This should be engaged using a risk-based approach or when there is already presumption of non-compliance to confirm any doubt on product quality or failure.
Detailed guidelines for in-country quality monitoring of health products can also be found in the following documents:
- Guide to Global Fund Policies on Procurement and Supply Management of Health Products, available here.
- Guidance on in-country quality monitoring of pharmaceutical products in Global Fund supported programs, available here.
- Global Fund information note on Quality Assurance Requirements for the Procurement of Masks and Respirators, available here.
- Global Fund Briefing Note on Quality Assurance Requirements for the Procurement of Oxygen Therapy Medical Devices, available here.
- Global Fund Briefing Note: Visual Inspection of Insecticide-treated Nets (ITNs), available here.
- Global Fund Briefing Note: Pre-Shipment Sampling, Testing and Reporting Results for Insecticide-treated Nets (ITNs), available here.
- Global Fund Briefing Note: Post-market surveillance of Insecticide-treated Nets (ITNs), available here.
- WHO Guidance for post-market surveillance and market surveillance of medical devices, including in vitro diagnostics, available here.